# Efficacy and Safety of Ravidasvir in Combination With Danoprevir/r and Ribavirin(RBV) in Treatment-naive, Non-cirrhotic, Chronic Hepatitis C Virus Genotype1 Infected Subjects.

> **NCT03362814** · PHASE2,PHASE3 · COMPLETED · sponsor: **Ascletis Pharmaceuticals Co., Ltd.** · enrollment: 425 (actual)

## Conditions studied

- HCV

## Interventions

- **DRUG:** Ravidasvir
- **DRUG:** Danoprevir
- **DRUG:** Ritonavir
- **DRUG:** Ribavirin 100 MG
- **DRUG:** Ravidasvir Placebo
- **DRUG:** Danoprevir Placebo
- **DRUG:** Ritonavir Placebo
- **DRUG:** Ribavirin Placebo

## Key facts

- **NCT ID:** NCT03362814
- **Lead sponsor:** Ascletis Pharmaceuticals Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-07-01
- **Primary completion:** 2018-12-12
- **Final completion:** 2019-04-24
- **Target enrollment:** 425 (ACTUAL)
- **Last updated:** 2020-07-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03362814

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03362814, "Efficacy and Safety of Ravidasvir in Combination With Danoprevir/r and Ribavirin(RBV) in Treatment-naive, Non-cirrhotic, Chronic Hepatitis C Virus Genotype1 Infected Subjects.". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03362814. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*